{"filing":{"accession_number":"0001829126-26-009237","cik":"0002079109","ticker":null,"company_name":"Veraxa Biotech AG - Post de-SPAC","form":"6-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079109/000182912626009237/veraxabiotechag_6k.htm"},"events":[{"id":29054,"run_id":26584,"accession_number":"0001829126-26-009237","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces achievement of a research milestone in a strategic collaboration between VERAXA and Secarna Pharmaceuticals to develop antibody-oligonucleotide conjugates (AOCs). The disclosure describes successful in vitro proof-of-concept results demonstrating the potential of combining both parties' technologies. While this is a partnership milestone rather than a discrete M\u0026A transaction, it represents a material operational/strategic development in VERAXA's pipeline advancement and technology validation that would be relevant to investors assessing the company's progress and competitive positioning in next-generation therapeutics.","company_name":"Veraxa Biotech AG - Post de-SPAC","ticker":null,"filing_date":"2026-08-24","form":"6-K","submitted_at":null,"items":[{"id":31200,"accession_number":"0001829126-26-009237","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces achievement of a research milestone in a strategic collaboration between VERAXA and Secarna Pharmaceuticals to develop antibody-oligonucleotide conjugates (AOCs). The disclosure describes successful in vitro proof-of-concept results demonstrating the potential of combining both parties' technologies. While this is a partnership milestone rather than a discrete M\u0026A transaction, it represents a material operational/strategic development in VERAXA's pipeline advancement and technology validation that would be relevant to investors assessing the company's progress and competitive positioning in next-generation therapeutics.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:39:38.012670+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31200,"accession_number":"0001829126-26-009237","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces achievement of a research milestone in a strategic collaboration between VERAXA and Secarna Pharmaceuticals to develop antibody-oligonucleotide conjugates (AOCs). The disclosure describes successful in vitro proof-of-concept results demonstrating the potential of combining both parties' technologies. While this is a partnership milestone rather than a discrete M\u0026A transaction, it represents a material operational/strategic development in VERAXA's pipeline advancement and technology validation that would be relevant to investors assessing the company's progress and competitive positioning in next-generation therapeutics.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:39:38.012670+00:00","company_name":"Veraxa Biotech AG - Post de-SPAC","ticker":null,"filing_date":"2026-08-24"}]}